Log in to your Inderes Free account to see all free content on this page.
Bavarian Nordic
163.8
DKK
-1.18 %
Less than 1K followers
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-1.18%
-3.82%
-13.49%
-17.65%
-31.12%
-2.88%
+5.88%
+32.52%
+14.84%
Bavarian Nordic is a biochemistry company. Today, the company specializes in the development, manufacture, and distribution of vaccines against infectious diseases in connection with cancer treatment. In addition, vaccines against other serious diseases such as Ebola and cervical cancer are also being developed. The largest operations are located in Europe and in the U.S. Bavarian Nordic was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Read moreMarket cap
12.92B DKK
Turnover
11.42M DKK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
9.4.
2025
General meeting '25
9.5.
2025
Interim report Q1'25
22.8.
2025
Interim report Q2'25
All
Research
Webcasts
Press releases
ShowingAll content types
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio